References
- The human genome at ten. Nature464(7289), 649–650 (2010).
- Collins F. Has the revolution arrived? Nature464(7289), 674–675 (2010).
- Venter JC. Multiple personal genomes await. Nature464(7289), 676–677 (2010).
- Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26, 1135–1145 (2008).
- Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med.4(4), 583–586 (2010).
- Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Pers. Med.7(4), 347–350 (2010).
- Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature456, 728–731 (2008).
- Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med.363(2), 166–176 (2010).
- Frazer KA, Ballinger DG, Cox DR et al; International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature449(7164), 851–861 (2007).
- Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med.362(11), 986–993 (2010).
- Welch GH. Screening mammography – a long run for a short slide? N. Engl. J. Med.363, 1276–1278 (2010).
- Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat. Rev. Urol.7(9), 487–493 (2010).
- Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
- Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
- Katsnelson A. Genomics goes beyond DNA sequence. Nature465(7295), 145 (2010).
- Time for the epigenome. Nature463(7281), 587 (2010).
- Beaudet AL. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature466(7308), 816–817 (2010).
- Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N. Engl. J. Med.363(12), 1099–1103 (2010).
- Annes JP, Giovanni MA, Murray MF. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med.363(12), 1100–1101 (2010).
- Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature461(7265), 747–753 (2009).
- Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
- Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456, 738–744 (2008).
- Roukos DH, Katsios C, Liakakos T. Genotype–phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn.10(5), 541–545 (2010).
- Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3), 283–287 (2010).
- Ng AC. Integrative systems biology and networks in autophagy. Semin. Immunopathol. DOI: 10.1007/s00281-010-0225-9 (2010) (Epub ahead of print).
- Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell128, 225–231 (2007).
- Werner T. Next generation sequencing in functional genomics. Brief Bioinform.11(5), 499–511 (2010).
- Heard E, Tishkoff S, Todd JA et al. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet.11(10), 723–733 (2010).
- Breitkreutz A, Choi H, Sharom JR et al. A global protein kinase and phosphatase interaction network in yeast. Science328(5981), 1043–1046 (2010).
- Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. DOI:10.1038/tpj.2010.81 (2010) (Epub ahead of print).
- Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J. Clin. Oncol.26(20), 3310–3316 (2008).
- Roukos DH. Bionetworks-based personalized medicine versus comparative–effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn.10(3), 247–250 (2010).
- Wood SN. Statistical inference for noisy nonlinear ecological dynamic systems. Nature466(7310), 1102–1104 (2010).
- Via M, Gignoux C, Burchard EG. The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med.2(1), 3 (2010).
- International Cancer Genome Consortium. International network of cancer genome projects. Nature464, 993–998 (2010).
- Katsnelson A. Genomics goes beyond DNA sequence. Nature465(7295), 145 (2010).
- Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices7(6), 723–726 (2010).
- Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010).
Websites
- US FDA. Medical devices. Letters to industry www.fda.gov/MedicalDevices/ResourcesforYou/Industry/ucm111104.htm
- US FDA. Medical devices, Array-Based Cytogenetic Tests: Questions on Performance Evaluation, Result Reporting and Interpretation, June 30, 2010 www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm214671.htm
- US FDA. Medical devices. FDA/CDRH Public Meeting: Oversight of Laboratory Developed Tests (LDTs), July 19–20, 2010 www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm